drugset
drugset / Trial / NCT00909506

Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients

NCT00909506 ↗

Phase 2 Completed 105 enrolled Seoul National University Hospital
RandomizedParallel-groupDouble-blindPrevention

Summary

The investigators hypothesize that adjuvant metformin use in breast cancer patients with overweight or pre-diabetes mellitus (DM) may improve their body condition including weight loss. In this study, the investigators aim to test the efficacy and safety of adjuvant metformin for operable breast cancer patients with overweight or pre-DM.

Timeline

Start
2009-06
Primary completion
2011-03
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 500 mg Oral
Comparator Metformin Small molecule 1000 mg Oral

Indications

breast cancer